-
Sawai Group Holdings Announces Change of Representative Directors and Corporate Officers
-
Sawai Group Reports First Half of Quarter FY2022 Financial Results
-
Sawai Group Reports First Quarter FY2022 Financial Results
-
Sawai Group Reports FY2021 Financial Results
-
Sawai Group Reports Third Quarter FY2021 Financial Results
-
Sawai Group Holdings and ORIX Agree on Conclusion of Transfer Agreement with Kobayashi Kako -Toward Early Establishment of In-house Annual Production Capacity of 20 Billion Tablets or More-
-
Posted the Supplementary Document Associated with Conclusion of Asset Transfer (Acquisition) Agreement
-
Sawai Group Reports First Half of FY2021 Financial Results
-
Integrated Report 2021 has been released
-
Upsher-Smith Launches Three Additional Strengths of Isotretinoin Capsules
-
Upsher-Smith Launches Carbamazepine Extended-Release Tablets, USP
-
Sawai Receives Approvals for Four Generic Drugs with Eight Strengths
-
Sawai Group Reports First Quarter FY2021 Financial Results
-
Upsher-Smith Launches Isotretinoin Capsules
-
Sawai Launches Eight Generic Drugs with 23 Strengths
-
Upsher-Smith and Rafarm Announce Launch of Moxifloxacin Ophthalmic Solution, USP 0.5%
-
Sawai Reports FY2020 Financial Results
-
Sawai Group Holdings Announces Posting of Impairment Loss and Revision of Forecast at Sawai Pharmaceutical
-
Message from the Chairman and Group CEO
